Closed

anti-tyrosinase (aa369-377) TCR, pCDTCR1 (TCR-L118Z)

The vector of anti-tyrosinase T cell receptor (TCR) is constructed for the engineering of T cell to target Human tyrosinase. The T cells are genetically modified through transduction with a retroviral vector expressing tyrosinase-specific T cell receptor. And the vector product was designed for the treatment of Melanoma.

Details

  • Target
  • tyrosinase
  • Target Species
  • Human
  • Epitope
  • YMNGTMSQV
  • Format
  • Murinized and Cysteine-modified
  • HLA
  • HLA-A2
  • Targeting Diseases
  • Melanoma
  • Vector Name
  • pCDTCR1
  • Vector Length
  • 8kb
  • Vector Type
  • Lentiviral
  • Antibody Host
  • Murinized (from Human)

Target

  • Gene Name
  • Tyrosinase
  • Official Symbol
  • TYR
  • Synonyms
  • TYR; Tyrosinase; Oculocutaneous Albinism IA; Tumor Rejection Antigen AB; Monophenol Monooxygenase; EC 1.14.18.1; LB24-AB; SK29-AB
  • Introduction
  • The enzyme encoded by this gene catalyzes the first 2 steps, and at least 1 subsequent step, in the conversion of tyrosine to melanin. The enzyme has both tyrosine hydroxylase and dopa oxidase catalytic activities, and requires copper for function. Mutations in this gene result in oculocutaneous albinism, and nonpathologic polymorphisms result in skin pigmentation variation. The human genome contains a pseudogene similar to the 3' half of this gene.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry
Products

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.